The maintenance of an Equal-Weight rating and a $7 price target by Morgan Stanley suggests a neutral outlook on Exscientia's stock. This indicates that the analyst believes the stock is fairly valued at its current price, implying no significant short-term price movement is expected based on this analysis alone.